Responses
Clinical/translational cancer immunotherapy
Original research
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
Compose a Response to This Article
Other responses
No responses have been published for this article.